原发性醛固酮增多症患者心血管并发症研究进展及防治策略  

Research progression and comprehensive management of cardiovascular complications in patients with primary aldosteronism

作　　者：任艳[1,2] 许晨晓 REN Yan;XU Chengxiao(Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;Adrenal Center,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西医院内分泌代谢科,成都610041 [2]四川大学华西医院肾上腺疾病诊治中心,成都610041

出　　处：《西南医科大学学报》2023年第5期380-386,共7页Journal of Southwest Medical University

基　　金：四川省科技厅重点研发项目(23ZDYF2116);四川大学华西医院临床孵化项目重大项目(2021HXFH008)。

摘　　要：原发性醛固酮增多症(primary aldosteronism,PA;简称原醛症)发生机制为肾上腺皮质醛固酮自主高分泌,引起机体一系列病理生理改变,导致继发性高血压及心血管并发症。该病患病率高,筛查率低,心血管损害严重,国内外共识均强调以预防靶器官损害、降低并发症为主要治疗目标。早期识别原醛症患者的心血管损害,予以适当有效的干预措施对改善患者的心血管预后具有重要价值。本文就原醛症患者心脏和血管病变研究及诊疗进展做一述评,以期为该类患者心血管并发症的早期识别和综合防治提供参考。Primary aldosteronism,also known as PA,is characterized by autonomous overproduction of aldosterone in the adrenal cortex,leading to a series of pathophysiological changes and subsequent secondary hypertension and cardiovascular complications.Due to the high prevalence,low screening rate and serious cardiovascular damage,both domestic and international consensus emphasize the prevention of target organ damage and reduction of complications as the main therapeutic goals.Early identification and appropriate intervention of cardiovascular damage in patients with primary aldosteronism are of great value to improve the cardiovascular prognosis.This article focused on the progress of research and comprehensive intervention of cardiovascular complications in patients with primary aldosteronism,with the aim of providing guidance for early identification and management of cardiovascular complications in these patients,and thus improving long-term prognosis.

关 键 词：原发性醛固酮增多症 心血管并发症 防治策略 

分 类 号：R586[医药卫生—内分泌]